The utility of Xenon-133 liver scan in the diagnosis and management of nonalcoholic fatty liver disease

Said A. Al-Busafi*, Peter Ghali, Philip Wong, Javier A. Novales-Diaz, Marc Deschênes

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is an important and common condition affecting approximately 20% of the general population. Given the limitation of radiological investigations, diagnosis often requires a liver biopsy. OBJECTIVE: To compare Xenon-133 (Xe-133) liver scanning with ultrasonography in the diagnosis of NAFLD. METHODS: From January 2003 to February 2007, 258 consecutive patients with suspected NAFLD underwent Xe-133 liver scanning at Royal Victoria Hospital (Montreal, Quebec). Of these, 43 patients underwent ultrasonography and liver biopsy for the evaluation of NAFLD. Patients with other liver diseases and significant alcohol consumption were excluded. Two nuclear medicine physicians assessed liver Xe-133 uptake and measured the grade of steatosis using a standardized protocol. The degree of steatosis was determined from biopsy specimens assessed by two hepatopathologists. RESULTS: NAFLD was identified by liver biopsy in 35 of 43 patients (81.4%). Xe-133 scan demonstrated 94.3% sensitivity (95% CI 81.4% to 98.4%) and 87.5% specificity (95% CI 52.9% to 99.4%) for the presence of NAFLD. The positive and negative predictive values for detection of steatosis by Xe-133 scan were 97.1% (95% CI 85.1% to 99.8%) and 77.8% (95% CI 45.3% to 93.7%), respectively. The positive and negative likelihood ratios were 7.54 (95% CI 1.20 to 47.26) and 0.07 (95% CI 0.02 to 0.26), respectively. Two patients with NAFLD (5.7%) who had a negative Xe-133 scan result had histologically mild steatosis (<10%). The grade of steatosis on liver biopsy was highly correlated with the results of the Xe-133 scan (r=0.87; P<0.001). The sensitivity and specificity of ultrasound in diagnosing steatosis were 62.9% and 75%, respectively. CONCLUSION: Xe-133 liver scan proved to be a safe, reliable, noninvasive method for diagnosing and quantifying hepatic steatosis, and was superior to ultrasound.

Original languageEnglish
Pages (from-to)155-159
Number of pages5
JournalCanadian Journal of Gastroenterology
Issue number3
Publication statusPublished - Mar 2012


  • Nonalcoholic fatty liver disease
  • Ultrasonography
  • Xenon-133 liver scan

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'The utility of Xenon-133 liver scan in the diagnosis and management of nonalcoholic fatty liver disease'. Together they form a unique fingerprint.

Cite this